Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 21, 2026

Qualcomm Stockholders Back Board, Equity Plan; CEO Amon Highlights AI, Robotics and Data Center Push

View original at finance.yahoo.com
Qualcomm Stockholders Back Board, Equity Plan; CEO Amon Highlights AI, Robotics and Data Center Push Qualcomm logo Key Points Stockholders approved all board-recommended items including the election of 11 directors, ratification of PwC as auditor, approval of the amended 2023 long-term incentive plan with a 24 million…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Qualcomm is diversifying beyond handsets into personal AI, wearables, PCs, automotive, edge networking and industrial IoT

    60% confidence

  • Qualcomm is returning approximately 100% of free cash flow to shareholders

    60% confidence

  • Qualcomm expects data center revenue to become financially material in fiscal 2027

    60% confidence

  • Qualcomm has formally entered advanced robotics with Dragonwing IQ 10 series support for AMRs and humanoids

    60% confidence

Data points we hold from this source

Qualcomm Incorporated · dividend per share increase0.03 USD
Qualcomm Incorporated · board size11 directors
Qualcomm Incorporated · free cash flow return rate100 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com